Your search for non small cell lung cancer returned 181 results

Daiichi Sankyo and ArQule announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197 in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

Alder Biopharmaceuticals announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518.

ArQule and Daiichi Sankyo announced the presentation of data from a Phase 2 trial showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer (NSCLC).

Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.

There was no improvement in overall survival with bevacizumab.

There was an improvement in progression-free survival despite crossover.

Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC).

KAEL-GemVax announced results from its Phase 2 study of vaccination with the telomerase peptide GV1001 after chemoradiotherapy in Stage III non-small cell lung cancer (NSCLC) patients.

Synta announced results from its Phase 2 study of ganetespib (STA-9090) for the treatment of NSCLC.

Eli Lilly and Bristol-Myers Squibb announced that they have stopped enrollment in one of their two global Phase 3 studies evaluating necitumumab as a first-line treatment for advanced non-small cell lung cancer (NSCLC).